We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr Jan Schmidt-Brand has been Chief Executive Officer of Heidelberg Pharma AG since 2014 and Chief Financial Officer since 2012. Until the acquisition by WILEX AG (former name of the Company), Dr Schmidt-Brand held the position of CEO/CFO in the former Heidelberg Pharma GmbH. The doctor of law has over 20 years’ experience in leading positions in the commercial as well as the fiscal sector of pharmaceutical companies. From 1997 to 2001 he was Managing Director of EBEWE Arzneimittel GmbH, an Austrian BASF Pharma subsidiary. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department with a general commercial power of attorney (“Prokurist”). Dr Jan Schmidt-Brand studied law, business management and French at the universities of Bayreuth and Geneva and obtained his doctoral degree from the University of Mannheim. He has been member of the board of directors of BIO Deutschland e.V.
This speaker's sessions: